Mpox (formerly known as monkeypox), an infectious disease caused by the monkeypox virus (MPXV), has been endemic in regions of Central and Western Africa. In 2022, the global spread of the clade IIb MPXV led to a multinational outbreak, primarily affecting sexual transmission networks among men who have sex with men. Despite interventions, new cases have continued to emerge. In Africa, the spread of a novel strain of clade I MPXV, clade Ib, has prompted a Public Health Emergency of International Concern designation by the World Health Organization in August 2024. This article provides an updated overview of the epidemiology, systemic, and ocular manifestations, highlighting the clinical features, diagnostic testing, and implications relevant to ophthalmologists and eye care providers, including infection prevention and control measures. The ocular manifestations of mpox primarily involve the ocular surface and anterior segment, with presentations ranging from conjunctivitis to severe, vision-threatening keratitis and uveitis. While the 2022 to 2024 Clade IIb outbreak has shown a lower incidence of ocular involvement compared with previous outbreaks, the potential for significant visual morbidity remains. Treatment involves both systemic and topical therapies, with tecovirimat being the primary systemic option, though its efficacy and ophthalmic bioavailability remain under investigation. Ongoing surveillance and research are essential to further understand the epidemiology and ophthalmic features of mpox and, ultimately, to optimize prevention and treatment strategies for patients.

Introduction: Highly Pathogenic Avian Influenza (HPAI) A(H5N1) represents a growing public health challenge, given broadening zoonotic vectors, with a previously reported human mortality rate of roughly 50%. Late March 2024 marked the start of a new outbreak of HPAI A(H5N1) in the United States. While offering unique public health challenges, this outbreak also provides insight into clinical presentation and ocular involvement implications, transmission vectors, and the implementation of successful surveillance strategies. Objectives: This review seeks to highlight current and historical outbreak trends, transmission and ocular tropism significance, and strategies to mitigate viral spread. Methods: A comprehensive narrative literature review was completed using PubMed database as well as local, federal, and international public health press releases. Discussion: The 2024 US outbreak of H5N1 demonstrates the unique adaptability of the virus. Traditionally transmitted to humans via infected poultry, this outbreak marks the first confirmed case of dairy cow-transmitted human infection. Unlike many past H5N1outbreaks, the majority of patients in the current US outbreak have presented with conjunctivitis either alone or alongside systemic symptoms. This ocular-specific disease manifestation offers new clinical and screening implications. Awareness of ophthalmic involvement among physicians and public health organizations can help guide screening candidates and identify potential infections.